Mantle Cell Lymphoma Clinical Trials and Treatments

Mantle cell lymphoma begins in B cells from the mantle zone, the outer ring of a lymph node's follicle. Its hallmark is a swap between chromosomes 11 and 14, written t(11;14), which makes the cells overproduce cyclin D1, a protein that drives cell division. A 2017 review in the American Journal of Hematology reports that cyclin D1 is found in 98% of cases, and that a missing SOX11 protein or a low Ki-67 growth score may point to a slower-growing form (Vose, 2017).

The most common symptoms of Mantle Cell Lymphoma include Swollen lymph nodes in the neck, armpit or groin, Fatigue and weakness, Fever and night sweats, Unexplained weight loss and loss of appetite, Indigestion or belly symptoms when the gut is involved, among others. About 1 in 200,000 people (Cleveland Clinic). Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Mantle Cell Lymphoma from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Mantle cell lymphoma has more than 100 recruiting or soon-to-open trials. Several large trials test new combinations: BeOne Medicines compares sonrotoclax plus zanubrutinib with zanubrutinib alone in relapsed disease (NCT06742996), InnoCare tests orelabrutinib with bendamustine and rituximab in untreated disease in people 60 and older in China (NCT06363994), and AstraZeneca studies acalabrutinib with R-CHOP in Spain (NCT07029737).

Yes, several. FDA-approved medicines for mantle cell lymphoma include the BTK inhibitors Calquence (acalabrutinib), Brukinsa (zanubrutinib) and Jaypirca (pirtobrutinib), the BCL-2 inhibitor Beqalzi (sonrotoclax), Velcade (bortezomib), Revlimid (lenalidomide), and the CAR T-cell therapies Tecartus and Breyanzi. Each is approved for a specific stage, such as untreated disease or disease that came back after a BTK inhibitor, and several are accelerated approvals based on response rate. Imbruvica (ibrutinib) no longer lists mantle cell lymphoma on its label.

Mantle cell lymphoma starts when B cells in the mantle zone of a lymph node pick up a swap between chromosomes 11 and 14, written t(11;14). The swap makes the cells overproduce cyclin D1, a protein that drives cell division, and a 2017 review in the American Journal of Hematology reports cyclin D1 in 98% of cases. The change happens during life and is not inherited. Cleveland Clinic says researchers do not know what sets it off, and that people aged 60 to 70 have a slightly higher risk.

Mantle cell lymphoma is not inherited, so testing looks at the lymphoma cells, not the genes a person was born with. A biopsy checks for cyclin D1 or the t(11;14) swap to confirm the diagnosis, and labs often measure Ki-67, a growth score that helps estimate how fast the lymphoma may grow. Trial teams often ask for these results, so a copy of the pathology report is useful.

Eligibility for Mantle Cell Lymphoma clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Mantle Cell Lymphoma clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.